B. Clotet

Type de document

Articles (6)

Co-auteur

Date

Source

Mot-clé

immunité (3) Treatment (3) Immunity (3) thérapie (2) étable (2) association (2) infection (2) effet (2) ADN (2) Therapeutics (2) T cells (2) Social groups (2) RNA (2) Proportion (2) Population (2) Infection (2) DNA (2) Population (2) résistance (2) roman (2) administration (1) spectacle (1) mise sous écran protecteur (1) sécurité (1) risque (1) bassin de retenue (1) contrôle qualité (1) persistance (1) art (1) nausée (1)

Documents écrit par B. Clotet (6) | parle de B. Clotet (0)

Dissemination of Mycobacterium tuberculosis is associated to a SIGLEC1 null variant that limits antigen exchange via trafficking extracellular vesicles.
S. Benet et al.
Enhancement of Antiviral CD8+ T-Cell Responses and Complete Remission of Metastatic Melanoma in an HIV-1-Infected Subject Treated with Pembrolizumab.
C. Gálvez et al. (1 déc. 2019)
Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption.
J.K. Rockstroh et al. (2019)
Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO.
J.M. Molina et al. (2014)
A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A.
J. Lane et al. (2013)
Siglec-1 is a novel dendritic cell receptor that mediates HIV-1 trans-infection through recognition of viral membrane gangliosides.
M. Lorizate et al. (2012)